Du forlater nå GSKs nettsider

Denne lenken tar deg til en nettside som ikke tilhører GSK. GSK er ikke ansvarlig for, går ikke god for og aksepterer intet ansvar for informasjon eller meninger på nettsteder til tredjeparter

Fortsett

Tilbake

2DR approach1

An Evolution in the Treatment of HIV

With treatment, people living with HIV are now expected to have a near normal life expectancy.

  • Based on results from the Antiretroviral Therapy Cohort Collaboration, a 20-year-old starting HIV therapy during 2008 to 2010 can expect to see their 78th birthday.2 
  • The majority of time on therapy is spent maintaining virological suppression.2

Streamlining therapy to 2 drugs following suppression can reduce ARV exposure and potential associated toxicities3 

2dr journey

Referanser

  1. JULUCA▼ preparatomtale 
  2. The Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;1-9 (published online May 10). http://dx.doi.org/10.1016/S2352-3018(17)30066-8. Accessed July 18, 2017.
  3. Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018;391(10123):839–849.